Patents by Inventor John Michael Berry

John Michael Berry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF PRODUCING INFLUENZA VACCINE COMPOSITIONS
    Publication number: 20160051660
    Abstract: Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.
    Type: Application
    Filed: March 4, 2015
    Publication date: February 25, 2016
    Inventors: George Robert TRAGER, Richard M. Schwartz, Vu Truong-Le, Luisa Yee, John Michael Berry, Weidong Cui
  • Non-tumorigenic MDCK cell line for propagating viruses
    Patent number: 8748174
    Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: June 10, 2014
    Assignee: MedImmune, LLC
    Inventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
  • NON-TUMORIGENIC MDCK CELL LINE FOR PROPAGATING VIRUSES
    Publication number: 20120115206
    Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
    Type: Application
    Filed: January 20, 2012
    Publication date: May 10, 2012
    Applicant: Medlmmune Way
    Inventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
  • Non-tumorigenic MDCK cell line for propagating viruses
    Patent number: 8119388
    Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: February 21, 2012
    Assignee: Medimmune, LLC
    Inventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
  • NON-TUMORIGENIC MDCK CELL LINE FOR PROPAGATING VIRUSES
    Publication number: 20100112000
    Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
    Type: Application
    Filed: January 13, 2010
    Publication date: May 6, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Richard SCHWARTZ, John Michael Berry, Ajit SUBRAMANIAN, Xiao SHI
  • Non-tumorigenic MDCK cell line for propagating viruses
    Patent number: 7670837
    Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: March 2, 2010
    Assignee: Medimmune, LLC
    Inventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
  • Methods of producing influenza vaccine compositions
    Patent number: 7262045
    Abstract: Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: August 28, 2007
    Assignee: MedImmune Vaccines, Inc.
    Inventors: Richard Schwartz, John Michael Berry, Weidong Cui